Network Pharmacology Analysis of Orally Bioavailable SARS-CoV-2 Protease Inhibitor Shows Synergistic Targets to Improve Clinical Efficacy
Keywords:Molecular interaction, Protease inhibitor, SARS-CoV-2, Antiviral, Coronavirus
Introduction: Orally bioavailable SARS-CoV-2 antiviral drugs will significantly improve the clinical management of the disease. PF07321332 (PF32) one such orally bioavailable SARSCoV- 2 protease inhibitor which can be helpful to prevent viral replication in the host. Materials and Methods: Hence this study evaluated the network pharmacology of PF32 using established methods to predict its potential safety and efficacy. Results: PF32 was selective against SARS-CoV-2 proteases without any affinity against SARS-CoV-2 RNA polymerase or its spike protein. While PF32 showed pharmacologically relevant affinity against several targets in human tissues. The target profiling of PF32 indicated a fourfold selectivity towards several proteases in human tissues with an affinity (IC50) ranging from 26 to 41 nM. Conclusion: The predicted inhibitory effects of PF32 against both host and viral proteases may have synergistic effects for superior clinical efficacy.
How to Cite
Copyright (c) 2021 Phcog.net
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.